Navigation path

ATHEROREMO

print

European Collaborative Project on Inflamation and Vascular Wall Remodelling in Atherosclerosis

Coordinator: Reijo LAAKSONEN
Project Number: 201668
EC contribution: 11,691,180.00
Project website: http://www.atheroremo.org/

The health of the EC population has never been better. However, serious public health problems remain, which cannot be ignored including high levels of premature death due to cardiovascular diseases. Thus, new preventive, diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases are needed. The atherosclerotic changes of the vascular wall are central in the development of cardiovascular complications. The traditional view that atherosclerosis is simply a lipid storage disease has recently been challenged by evidence that inflammation plays a central role in all stages of atherosclerosis. However, molecular mechanisms linking inflammation to atherosclerosis development are not fully understood, and this has severely hampered the advance of diagnostic and therapeutic programs. AtheroRemo aims to identify novel inflammatory mechanisms in vascular remodelling by combining the exploration of human biobanks with animal models and established cellular models. This new knowledge will be used to develop new preventive, diagnostic and therapeutic strategies against atherosclerotic cardiovascular disease. AtheroRemo contains several unique strengths:

  1. Outstanding expertise on immunity and inflammation. Our expertise facilitates the breakthroughs in the immuno-inflammatory targeted vascular treatments.
  2. Finest European cohorts to search for molecular mechanisms behind atherosclerosis development allowing us to combine underlying genetics with lipidomic profiles in multiple cohorts in order to obtain risk factors and biomarker panel related to inflammatory remodelling.
  3. Accelerated target validation with novel liposomal-targeted delivery of nucleic acid-based therapeutics in appropriate animal models.

Four SME partners able to exploit the new knowledge support AtheroRemo research. Thus, we expect to translate a number of novel findings into potential clinical applications such as new diagnostic tools (biomarkers) and therapeutics.

Top ^